Fontolizumab

Fontolizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target interferon gamma
Identifiers
CAS Number 326859-36-3 N
ATC code None
ChemSpider none
UNII 6J92H2439Z YesY
KEGG D04242 YesY
Chemical data
Molar mass ca. 150 kg/mol
 NYesY (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  2. ↑ Reinisch, W; De Villiers, W; Bene, L; Simon, L; Rácz, I; Katz, S; Altorjay, I; Feagan, B; et al. (2009). "Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory bowel diseases 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334.
  3. ↑ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at ClinicalTrials.gov


This article is issued from Wikipedia - version of the Saturday, January 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.